Electronic Prior Authorization: The Vendor Landscape

A field guide to the electronic prior authorization (ePA) market: network incumbents, provider-side platforms, payer-side decisioning tools, and the AI-native newcomers reshaping the space ahead of the 2027 CMS API deadline.

Published July 21, 2026

Reimbursement & Prior Auth

Electronic prior authorization (ePA) vendors fall into four broad segments: network incumbents that move PA transactions between providers, pharmacies, and payers at scale; provider-side platforms that help practices and health systems submit and track requests; payer-side decisioning systems that help health plans review them; and a fast-growing group of AI-native companies automating the work end to end. No single vendor covers the whole journey, so most pharma manufacturers, providers, and plans end up combining two or more of these segments — and regulatory deadlines arriving between 2026 and 2027 are forcing every one of them to modernize at once.

Why the market is moving now

Two forces are reshaping the ePA landscape simultaneously.

First, regulation. The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) applies to Medicare Advantage plans, state Medicaid and CHIP programs, Medicaid managed care, and Qualified Health Plans on the federal exchanges. As of January 1, 2026, affected payers must return expedited PA decisions within 72 hours and standard decisions within seven calendar days, and must give a specific reason with every denial. By January 1, 2027, they must also stand up FHIR-based APIs — including a dedicated Prior Authorization API — for checking requirements, submitting requests, and tracking status. Public reporting of PA metrics began in early 2026.

Second, industry pressure. In mid-2025, dozens of major insurers — including UnitedHealthcare, CVS Health’s Aetna, Cigna, Humana, and more than 30 Blue Cross Blue Shield plans — signed a voluntary pledge, coordinated with HHS and CMS, to reduce PA volume, honor existing authorizations when patients switch plans, and answer at least 80% of complete electronic PA requests in real time by 2027. Physicians remain skeptical: in the American Medical Association’s most recent survey of 1,000 physicians, respondents reported spending an average of 13 hours per week on roughly 40 prior authorizations, and only about a third believed the pledge would produce meaningful change.

The practical consequence: every payer touching government programs needs new PA infrastructure by 2027, every provider organization has an incentive to adopt electronic submission, and vendors in all four segments are racing to fill the gap.

The four segments of the ePA market

1. Network incumbents

These companies own the transaction rails that connect prescribers, pharmacies, PBMs, and payers. Their strength is reach; the trade-off is that they primarily standardize and route requests rather than eliminate them.

CoverMyMeds — the industry-standard pharmacy-benefit ePA network, part of McKesson, connecting tens of thousands of pharmacies and hundreds of thousands of providers. In June 2025 it acquired RxLightning (digital specialty enrollment) and FastAuth (automated medical prior authorization), extending its footprint from pharmacy-benefit PA into specialty enrollment and medical-benefit workflows.
Surescripts — the largest US e-prescribing network, now majority-owned by TPG, offering ePA and touchless PA automation alongside its Real-Time Prescription Benefit service that surfaces coverage and price at the point of prescribing.
Change Healthcare — the largest US clearinghouse, operating inside Optum since 2022, with PA transactions embedded in its broader eligibility and claims infrastructure.
Availity — a payer-provider network whose Essentials portal lets providers check authorization requirements and submit PAs with clinical attachments across many plans, and which supports FHIR-based PA APIs for CMS-0057-F compliance.
Rhyme — an EHR-integrated PA network uniting payers and providers for real-time, increasingly touchless decisions, processing millions of PAs annually for large health systems.

2. Provider-side platforms

These vendors sit inside practice, infusion-center, and hospital workflows, helping the submitting side assemble documentation and chase status.

SamaCare — focused on medical-benefit PA for buy-and-bill specialty drugs in physician practices and infusion centers; free to providers and funded through pharma manufacturer partnerships.
Valer — a cloud platform automating PA and referral submission and tracking across payers and service types for hospitals and health systems, with EHR integrations including Epic.
Infinx — combines AI software with global service teams for eligibility, benefits, PA, and denials management across the revenue cycle.
Humata Health — AI-driven “touchless” PA technology that assembles clinical documentation and flags likely denial reasons before submission.
PrescriberPoint — a free, AI-powered PA workflow platform for prescribers covering the full lifecycle from script capture through appeals.

Adjacent to this segment sit benefit-verification and document-intake specialists — such as Interra Health (formed in early 2026 from the merger of e-prescribing vendor DoseSpot, price-transparency network Arrive Health, and eligibility specialist pVerify, backed by Bain Capital Tech Opportunities), eBlu Solutions for infusion therapies, and zPaper for Salesforce-native document capture — that feed clean data into PA workflows.

3. Payer-side decisioning

On the other side of the transaction, health plans and PBMs buy software to intake, route, and decide PA requests — and to hit the new CMS turnaround clocks.

EviCore by Evernorth — the largest delegated utilization management company, making evidence-based PA determinations for health plans across imaging, oncology, cardiology, and specialty care.
Cohere Health — intelligent PA for health plans that auto-approves a large share of requests through clinical AI; the company raised a $90 million Series C in 2025.
Agadia Systems — PAHub, a utilization management platform automating pharmacy and medical PA for plans, PBMs, and TPAs, with FHIR interoperability for CMS-0057-F.
MHK — part of Hearst Health, unifying utilization management, pharmacy PA, and appeals/grievances for Medicare, Medicaid, and commercial lines.
Banjo Health — AI-driven PA decisioning that turns clinical criteria into decision trees for plans and PBMs.
Itiliti Health — FHIR-native ePA infrastructure implementing the CRD, DTR, and PAS transactions that CMS-0057-F requires.
Anterior — clinician-led AI for payer clinical review, which raised $40 million in early 2026.

4. AI-native automation

The newest segment treats prior authorization as an automation problem rather than a transaction-routing problem. These companies use large language models, vision models, and voice agents to do the work humans previously did — reading referrals, filling forms, calling payers, writing appeals.

Forus (formerly Tandem) — an AI medication-access network embedded in physician workflows, automating benefit verification, PA, financial assistance, and pharmacy routing; it raised $160 million at a reported $1 billion valuation in May 2026.
Tennr — healthcare-specific vision-language models that read faxed referrals and clinical documents and evaluate them against payer criteria; raised a $101 million Series C in 2025.
Infinitus Systems and Prosper AI — voice AI agents that make the payer phone calls (benefit verification, PA status, claims follow-up) that still dominate specialty access work.
Mandolin and Trellis AI — AI agents automating the referral-to-reimbursement path for infusion centers, specialty pharmacies, and health systems.
Develop Health and Silna Health — GenAI-native platforms for pharmacy-benefit verification and specialty-specific PA in EHR and outpatient workflows.
Claimable — a patient-facing AI appeals platform for denied claims.

How the segments compare

Segment	Buyer	Core value	Watch-outs
Network incumbents	Payers, pharma, EHRs	Reach, standard transactions, EHR integration	Routes requests; does not remove manual clinical work
Provider-side platforms	Practices, infusion centers, health systems	Faster submission, status tracking, fewer denials	Coverage varies by benefit type (medical vs. pharmacy)
Payer-side decisioning	Health plans, PBMs	Turnaround compliance, auto-approval, audit trails	Delegated UM models face regulatory and clinical scrutiny
AI-native automation	Providers, pharma hubs, specialty pharmacies	Labor replacement across intake, calls, forms, appeals	Young companies; validate accuracy and integration claims

Practical takeaways

Buyers should start from the benefit type and the workflow seat, not from the vendor list. Pharmacy-benefit PA for retail drugs is largely a solved routing problem dominated by the networks; medical-benefit PA for buy-and-bill specialty drugs is where provider-side platforms and AI-native vendors add the most value; and payers facing the January 2027 FHIR API deadline are effectively required to buy or build compliant infrastructure now. For pharma manufacturers funding access programs, the most useful diligence questions are concrete: which benefit types and payers a vendor actually covers, what share of transactions complete without human touch, and how the vendor will interoperate with the CMS-mandated APIs once they go live. Given how quickly the AI-native segment is raising capital and signing customers, a vendor scan older than a couple of quarters is already out of date — compare current profiles before shortlisting.